EQT Life Sciences Leads Series B Extension in Noema Pharma, Raising Total Series B Financing to CHF 130 million
· Proceeds will be used to enable key late-stage clinical trial readouts for assets across several underserved neurological diseases with high unmet medical need. · EQT Life Sciences has led the extension, and joins a consortium of prominent global biotechnology investors. · The investment builds on EQT Life Sciences’ previous successful partnership with neurology-focused repeat entrepreneur and Noema Pharma CEO Ilise Lombardo, MDEQT Life Sciences is pleased to announce that the LSP 7 fund has invested in Noema Pharma (“the Company”). The clinical-stage biotech company headquartered